JP2010509205A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509205A5 JP2010509205A5 JP2009535189A JP2009535189A JP2010509205A5 JP 2010509205 A5 JP2010509205 A5 JP 2010509205A5 JP 2009535189 A JP2009535189 A JP 2009535189A JP 2009535189 A JP2009535189 A JP 2009535189A JP 2010509205 A5 JP2010509205 A5 JP 2010509205A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- heterocyclyl
- alkyl
- aryl
- cor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims 29
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 125000003118 aryl group Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 14
- 229910052757 nitrogen Inorganic materials 0.000 claims 13
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 239000004593 Epoxy Substances 0.000 claims 5
- -1 aromatic carbocyclic radical Chemical class 0.000 claims 5
- 125000004452 carbocyclyl group Chemical group 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 229920006395 saturated elastomer Polymers 0.000 claims 5
- 208000031886 HIV Infections Diseases 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 230000009385 viral infection Effects 0.000 claims 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 3
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims 3
- 229940125904 compound 1 Drugs 0.000 claims 3
- 229940125898 compound 5 Drugs 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 229940125782 compound 2 Drugs 0.000 claims 2
- 229940126214 compound 3 Drugs 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 claims 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 claims 1
- 241001115402 Ebolavirus Species 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000389 T-cell leukemia Diseases 0.000 claims 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- 125000002015 acyclic group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000003310 benzodiazepinyl group Chemical group N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 claims 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 241001493065 dsRNA viruses Species 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000001422 pyrrolinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 0 Cc(cc(cc1)S(Nc2ncccn2)(=*)=O)c1NC(C(NC(c1ccc[s]1)=O)=Cc1ccc[s]1)=O Chemical compound Cc(cc(cc1)S(Nc2ncccn2)(=*)=O)c1NC(C(NC(c1ccc[s]1)=O)=Cc1ccc[s]1)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85737806P | 2006-11-07 | 2006-11-07 | |
| US95983107P | 2007-07-17 | 2007-07-17 | |
| PCT/IL2007/001356 WO2008056356A2 (en) | 2006-11-07 | 2007-11-07 | Pyrimidine derivatives as posh and posh-ap inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010509205A JP2010509205A (ja) | 2010-03-25 |
| JP2010509205A5 true JP2010509205A5 (cg-RX-API-DMAC7.html) | 2010-12-24 |
Family
ID=39364907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535189A Pending JP2010509205A (ja) | 2006-11-07 | 2007-11-07 | Ｐｏｓｈ及びｐｏｓｈ−ａｐ阻害剤としてのピリミジン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8283355B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2083826A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2010509205A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007318922C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2668859A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008056356A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010322800A1 (en) * | 2009-11-30 | 2012-07-12 | Proteologics, Ltd. | Small pyrimidine derivatives and methods of use thereof |
| WO2013088445A1 (en) * | 2011-12-13 | 2013-06-20 | Proteologics Ltd | Pyrimidine derivatives for treatment of inflammatory diseases |
| GB201415688D0 (en) * | 2014-09-04 | 2014-10-22 | Univ Edinburgh | Method and Systems |
| CN108025034B (zh) * | 2015-07-15 | 2022-09-30 | 新加坡科技研究局 | 乙型肝炎病毒复制的调控 |
| US12059413B2 (en) | 2016-11-02 | 2024-08-13 | The Research Foundation For The State University Of New York | Methods of inhibiting viruses using compositions targeting TSG101-ubiquitin interaction |
| AR115697A1 (es) * | 2018-07-05 | 2021-02-17 | Bayer Ag | Tiofenocarboxamidas sustituidas y análogos de las mismas |
| BR112021019779A2 (pt) * | 2019-04-02 | 2022-01-04 | Yonsei Univ Univ Industry Foundation Uif | Novo composto e composição para prevenção ou tratamento de doenças respiratórias compreendendo os mesmos como ingrediente ativo |
| CN110760597B (zh) * | 2019-11-22 | 2022-08-23 | 西北农林科技大学 | 一种检测黄牛ncstn基因拷贝数变异的方法及其应用 |
| TW202527955A (zh) * | 2023-11-27 | 2025-07-16 | 美商尼坎醫療公司 | 用於經由泛素蛋白酶體途徑降解週期蛋白依賴性激酶２和週期蛋白依賴性激酶４的含有２，５－取代的嘧啶衍生物的雙功能化合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5734081A (en) | 1994-08-05 | 1998-03-31 | Warner-Lambert Company | Arylthio compounds |
| EP1341817A2 (en) | 2000-12-08 | 2003-09-10 | Novo Nordisk A/S | Tff peptides |
| FI116940B (fi) * | 2001-07-20 | 2006-04-13 | Juvantia Pharma Ltd Oy | Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet |
| EP1422228A1 (en) | 2001-08-08 | 2004-05-26 | Takeda Chemical Industries, Ltd. | BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE |
| FR2845382A1 (fr) * | 2002-10-02 | 2004-04-09 | Sanofi Synthelabo | Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique |
| CA2539227A1 (en) * | 2003-08-08 | 2005-02-17 | Vertex Pharmaceuticals Incorporated | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
| US20050214751A1 (en) * | 2004-03-02 | 2005-09-29 | Proteologics, Inc. | Inhibition of viral maturation, methods and compositions related thereto |
| US7671077B2 (en) * | 2004-07-19 | 2010-03-02 | Leu-Fen Hou Lin | Neuroprotective small organic molecules, compositions and uses related thereto |
-
2007
- 2007-11-07 US US12/312,416 patent/US8283355B2/en not_active Expired - Fee Related
- 2007-11-07 WO PCT/IL2007/001356 patent/WO2008056356A2/en not_active Ceased
- 2007-11-07 EP EP07827329A patent/EP2083826A4/en not_active Withdrawn
- 2007-11-07 AU AU2007318922A patent/AU2007318922C1/en not_active Ceased
- 2007-11-07 CA CA002668859A patent/CA2668859A1/en not_active Abandoned
- 2007-11-07 JP JP2009535189A patent/JP2010509205A/ja active Pending
-
2012
- 2012-10-04 US US13/645,465 patent/US20130131094A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010509205A5 (cg-RX-API-DMAC7.html) | ||
| ES2657687T3 (es) | Derivados de pirrolopirimidina para uso en el tratamiento de infecciones virales | |
| HRP20211224T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| AU2010244462B2 (en) | Dihydroorotate - dehydrogenase inhibitors as virostatic compounds | |
| JP2013518107A5 (cg-RX-API-DMAC7.html) | ||
| NZ627826A (en) | Antiviral combinations involving (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide | |
| NZ597544A (en) | Modified 4'-nucleosides as antiviral agents | |
| RU2018136104A (ru) | СОЕДИНЕНИЯ, ГЕТЕРОБИЦИКЛО-ЗАМЕЩЕННЫЕ-[1,2,4]ТРИАЗОЛО[1,5- c]ХИНАЗОЛИН-5-АМИНА, ОБЛАДАЮЩИЕ СВОЙСТВАМИ A2А АНТАГОНИСТОВ | |
| RU2012117829A (ru) | Фосфорамидатные производные нуклеозидов | |
| TW200630344A (en) | Tetracyclic indole derivatives as antiviral agents | |
| JP2009526761A5 (cg-RX-API-DMAC7.html) | ||
| RU2017135467A (ru) | Комбинированное лечение агонистом толл-подобного рецептора (tlr7) и ингибитором сборки капсида вируса гепатита в | |
| EA201171376A1 (ru) | Производные тиено[2,3-b]пиридина в качестве ингибиторов репликации вируса | |
| JP2010523522A5 (cg-RX-API-DMAC7.html) | ||
| DOP2015000079A (es) | Análogos de 2'-cloro nucleósido para infección por vhc | |
| EA201591027A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
| RU2018102449A (ru) | Производные пиразоло[1,5-a]триазин-4-амина, применимые в терапии | |
| JP2014518266A5 (cg-RX-API-DMAC7.html) | ||
| EA202090514A1 (ru) | Противовирусное средство против гепатита в | |
| RU2015120478A (ru) | Пери-карбинолы | |
| CA2862755A1 (en) | Antiviral compounds with a dibenzooxaheterocycle moiety | |
| RU2017103656A (ru) | Производные изоиндолинона, полезные в качестве противовирусных средств | |
| JP2013224953A5 (cg-RX-API-DMAC7.html) | ||
| US20210228601A1 (en) | Broad Spectrum Antiviral and Methods of Use | |
| AR065297A1 (es) | Formulaciones biodisponibles de compuestos heterociclicos |